Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocular Therapeutix Inc OCUL

Healthcare
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular... see more

Recent & Breaking News (NDAQ:OCUL)

Ocular Therapeutix™ to Participate in the 2018 Glaucoma 360 Meeting in San Francisco

Business Wire February 8, 2018

Ocular TherapeutixTM Announces Closing of Public Offering of Common Stock

Business Wire January 29, 2018

Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock

Business Wire January 25, 2018

A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Earnings, Economic Data

Benzinga.com  January 25, 2018

12 Stocks To Watch For January 25, 2018

Benzinga.com  January 25, 2018

11 Stocks Moving In Wednesday's After-Hours Session

Benzinga.com  January 24, 2018

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

Business Wire January 24, 2018

Ocular Therapeutix™ Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality

Business Wire January 8, 2018

Ocular Therapeutix™ Provides Legal Update

Business Wire December 22, 2017

Ocular Therapeutix™ to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference

Business Wire December 5, 2017

Robbins Arroyo LLP Investigates the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders

Business Wire November 20, 2017

Ocular Therapeutix™ Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Business Wire November 7, 2017

Ocular Therapeutix Inc to Host Earnings Call

Accesswire November 7, 2017

Ocular Therapeutix™ to Report Third Quarter 2017 Financial Results

Business Wire October 31, 2017

Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders

Business Wire October 24, 2017

Stock Performance Review on Biotech Industry -- Vertex Pharma, Axovant Sciences, Cerecor, and Ocular Therapeutix

PR Newswire September 28, 2017

Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders

Business Wire September 26, 2017

Ocular Therapeutix™ Appoints Donald Notman as Chief Financial Officer

Business Wire September 25, 2017

Ocular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer

Business Wire September 8, 2017

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

Business Wire September 6, 2017